The Future Of Rebates: MedPAC Will Be Watching For Pricing Law Impacts
The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on actual prescription drug spending – but immediate recommendations may not be viable given the changes coming from implementation of the Inflation Reduction Act.
You may also be interested in...
Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much
Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.
The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.